Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Up 71.4% in July

Key Points

• Adlai Nortye Ltd. experienced a significant increase in short interest, rising by 71.4% from 2,800 shares to 4,800 shares as of July 31st.
• Shares of Adlai Nortye opened at $1.69 and saw a decline of 3.4% on Monday, with a twelve-month trading range between $1.10 and $3.89.
• HC Wainwright downgraded the company's rating from "buy" to "neutral" on June 2nd.

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 4,800 shares, agrowthof71.4% from the July 15th total of 2,800 shares. Based on an average daily volume of 8,500 shares, the days-to-cover ratio is currently 0.6 days. Approximately0.0% of the company's stock are short sold. Approximately0.0% of the company's stock are short sold. Based on an average daily volume of 8,500 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Ratings Changes

Separately, HC Wainwright lowered Adlai Nortye from a "buy" rating to a "neutral" rating in a research report on Monday, June 2nd. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $9.00.

Adlai Nortye Stock Up 1.2%

NASDAQ ANL traded up $0.02 during trading hours on Thursday, hitting $1.69. The company had a trading volume of 6,013 shares, compared to its average volume of 11,489. The firm has a 50 day simple moving average of $1.55 and a 200 day simple moving average of $1.86. Adlai Nortye has a 52 week low of $1.10 and a 52 week high of $3.89. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.02.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.